Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, Francesco Patti, Francois Grand'Maison, Suzanne Hodgkinson, Pierre Grammond, Jeannette Lechner-Scott, Ernest Butler, Alexandre Prat, Marc Girard, Pierre Duquette, Richard A L Macdonell, Bianca Weinstock-Guttman, Serkan Ozakbas, Mark Slee, Maria Jose Sa, Vincent Van Pesch, Michael Barnett, Bart Van Wijmeersch, Oliver Gerlach, Julie Prevost, Murat Terzi, Cavit Boz, Guy Laureys, Liesbeth Van Hijfte, Allan G Kermode, Justin Garber, Bassem Yamout, Samia J Khoury, Daniel Merlo, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
IMPORTANCE: Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses. OBJECTIVES: To compare the effectiveness and persistence of dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis (RRMS) who discontinued natalizumab. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, patient data were collected from the MSBase registry between June 15, 2010, and July 6, 2021...
June 5, 2023: JAMA Neurology